SCHEMBL4152093

SCHEMBL4152093

FC(F)(F)c1cccc(C(c2cccc(C(F)(F)F)c2)N2CCNCC2)c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A4 P31645 1/20 0.60
MEN1 O00255 1/20 0.57
KMT2A Q03164 1/20 0.57
OPRD1 P41143 4/20 0.56
OPRM1 P35372 1/20 0.56
OPRK1 P41145 1/20 0.56
OPRL1 P41146 1/20 0.56
ALDH1A1 P00352 2/20 0.56
HTR3E A5X5Y0 1/20 0.56
HTR3B O95264 1/20 0.56
HTR1D P28221 1/20 0.56
HTR2C P28335 1/20 0.56
HTR3A P46098 1/20 0.56
HTR3D Q70Z44 1/20 0.56
HTR3C Q8WXA8 1/20 0.56
SIGMAR1 Q99720 1/20 0.56
MAPT P10636 1/20 0.55
THRB P10828 1/20 0.55
CACNA2D1 P54289 1/20 0.53
CACNA1B Q00975 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4135481 0.96 MEN1 (0.66) SLC6A4MEN1KMT2AOPRD1OPRM1
SCHEMBL10357009 0.87 TACR1 (0.53) SLC6A4MEN1KMT2AOPRD1OPRM1
SCHEMBL8964096 0.84 OPRD1 (0.57) SLC6A4MEN1KMT2AOPRD1OPRM1
SCHEMBL14747925 0.84 MEN1 (0.62) SLC6A4MEN1KMT2AOPRD1OPRM1
Hydrochloric Acid SCHEMBL2308818 0.84 SLC6A4 (0.56) SLC6A4ALDH1A1HTR3EHTR3BHTR1D
SCHEMBL27716757 0.84 SLC6A4 (0.48) SLC6A4MEN1KMT2AOPRD1OPRM1
SCHEMBL11376782 0.81 SLC6A4 (0.64) SLC6A4ALDH1A1HTR3EHTR3BHTR1D
SCHEMBL1743579 0.81 MEN1 (0.72) SLC6A4MEN1KMT2AOPRD1OPRM1
Hydrochloric Acid SCHEMBL11384541 0.80 SLC6A4 (0.62) SLC6A4ALDH1A1HTR3EHTR3BHTR1D
SCHEMBL5106757 0.80 CYP2D6 (0.61) SLC6A4MEN1KMT2AOPRD1OPRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9663476-B2 Glycine transporter-1 inhibitors AMGEN INC. (US) 2017-05-30 US disclosed
EP-2947067-A1 Glycine transporter-1 inhibitors Amgen, Inc (US) 2015-11-25 EP disclosed
US-20150307457-A1 GLYCINE TRANSPORTER-1 INHIBITORS AMGEN INC. (US) 2015-10-29 US disclosed
US-8735383-B2 Glycine transporter-1 inhibitors AMGEN INC. (US) 2014-05-27 US disclosed
EP-2041088-B1 GLYCINE TRANSPORTER-1 INHIBITORS AMGEN INC (US) 2014-01-08 EP disclosed
EP-2565183-A1 Glycine transporter-1 inhibitors Amgen Inc. (US) 2013-03-06 EP disclosed
US-20120195985-A1 GLYCINE TRANSPORTER-1 INHIBITORS AMGEN INC. (US) 2012-08-02 US disclosed
US-8183244-B2 Glycine transporter-1 inhibitors AMGEN INC. (US) 2012-05-22 US disclosed
US-20090227595-A1 GLYCINE TRANSPORTER-1 INHIBITORS HITCHCOCK STEPHEN 2009-09-10 US disclosed
US-7538114-B2 Glycine transporter-1 inhibitors AMGEN INC. (US) 2009-05-26 US disclosed
EP-2041088-A1 GLYCINE TRANSPORTER-1 INHIBITORS Amgen Inc. (US) 2009-04-01 EP disclosed
WO-2008002583-A1 GLYCINE TRANSPORTER-1 INHIBITORS AMGEN INC. (US) 2008-01-03 WO disclosed
US-20080004289-A1 Glycine transporter-1 inhibitors AMGEN INC. 2008-01-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090227595-A1 GLYCINE TRANSPORTER-1 INHIBITORS SLC18A2, SLC7A11, SLC6A5 SLC6A4 16/4885MEN1 2625/4885KMT2A 843/4885
US-20120195985-A1 GLYCINE TRANSPORTER-1 INHIBITORS SLC18A2, SLC6A5, SLC1A2 SLC6A4 13/4885MEN1 2632/4885KMT2A 947/4885
US-20080004289-A1 Glycine transporter-1 inhibitors SLC18A2, SLC7A11, SLC6A5 SLC6A4 16/4885MEN1 2625/4885KMT2A 843/4885
US-20150307457-A1 GLYCINE TRANSPORTER-1 INHIBITORS SLC18A2, SLC7A11, SLC6A5 SLC6A4 16/4885MEN1 2625/4885KMT2A 843/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.